BioCryst Pharmaceuticals, Inc. (BCRX)

From the record

BioCryst Pharmaceuticals, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

BioCryst Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $26 million in fiscal 2016 to $875 million in fiscal 2025, up 47.6% a year; it rose in 6 of 9 years; the deepest fall was 64% from fiscal 2019 to fiscal 2020; net income was positive in 1 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, BioCryst Pharmaceuticals, Inc.'s diluted share count grew about 5.5% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 10 sales (8 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioCryst Pharmaceuticals, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 166 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 123 cents per dollar of assets, and net share issuance: its share count grew 5.7% over the year (the filed statements).

From the record

BioCryst Pharmaceuticals, Inc.'s standing among 102 graded names in its industry family: revenue of $875 million in fiscal 2025 ranks in the top 10% by size; a net margin of 30.2% ranks in the top 8%; revenue growth of 47.8% a year over the last 3 filed years ranks in the top 22% (its annual reports).

From the record

BioCryst Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: no one files under a chief executive's title, so that part is not read; the 14 officers and directors filing in the last fifteen months have been on the record a median of 5.2 years (bottom 43%); 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (bottom 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

BioCryst Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $90 million against debt of $0 thousand leaves 17.5% of its assets as net cash, bottom 30% of its family; cash from operations less capital spending is 39.4% of revenue (top 5%); a gross margin of 97.8% (top 18%); research spending of 19% of revenue (bottom 15%) (its annual report).

From the record

BioCryst Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 47.8% a year over the last three filed years against 47.6% over all 10, speeding up (top 28% of its family); the newest year grew 94.2% (top 22%); research spending grew -13.1% a year (bottom 24%); capital spending grew 22.2% a year (top 16%) (its annual reports). BioCryst Pharmaceuticals, Inc. reported 4 product lines in fiscal 2025: ORLADEYO at $602 million (68%), License at $244 million (28%), Other Income From Contract With Customer at $29 million (3%), and 1 more; 2 of 3 grew against the year before (its annual report).

From the record

BioCryst Pharmaceuticals, Inc.'s newest year against its own record: revenue of $875 million in fiscal 2025 came in 50.5% above the $581 million its prior three years' pace pointed to (top 26% of its family); net income of $264 million against a prior three-year average of $188 million (top 5%); a net margin of 30.2% against -59.8% before (top 42%) (its annual reports).